EWTX
Edgewise Therapeutics, Inc. NASDAQ Listed Mar 26, 2021$36.81
+5.72%
vs $34.82
Mkt Cap $4.0B
52w Low $12.15
86.2% of range
52w High $40.77
50d MA $33.80
200d MA $25.99
P/E (TTM)
-22.6x
EV/EBITDA
—
P/B
7.2x
Debt/Equity
0.0x
ROE
-32.1%
P/FCF
-26.3x
RSI (14)
56.10
ATR (14)
$2.61
Beta
0.25
50d MA
$33.80
200d MA
$25.99
Avg Volume
1.6M
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
3415 Colorado Avenue · Boulder, CO 80303 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 36.99 | +2.7% | -3.8% | -0.7% | -2.2% | -1.6% | -0.7% | — |
| Feb 26, 2026 | AMC | -0.43 | -0.47 | -9.3% | 29.66 | -0.4% | +2.6% | -2.4% | -3.0% | +0.2% | -1.7% | — |
| Nov 6, 2025 | AMC | -0.40 | -0.39 | +2.5% | 17.09 | -0.2% | +0.4% | +6.5% | +17.5% | -1.4% | -3.5% | — |
| Aug 7, 2025 | AMC | -0.42 | -0.34 | +19.0% | 12.95 | +0.3% | -2.1% | +2.4% | +3.1% | +2.5% | +1.5% | — |
| May 8, 2025 | AMC | -0.45 | -0.43 | +4.4% | 14.70 | +1.7% | -0.8% | +1.6% | +0.5% | -2.3% | -0.7% | — |
| Mar 3, 2025 | AMC | -0.39 | -0.42 | -7.7% | 25.53 | -1.6% | -4.0% | +9.0% | +5.3% | -0.4% | -1.7% | — |
| Nov 7, 2024 | AMC | -0.37 | -0.36 | +2.7% | 35.43 | -1.3% | +2.7% | -2.9% | -0.4% | -5.5% | -1.2% | — |
| Aug 8, 2024 | AMC | -0.36 | -0.34 | +5.6% | 16.19 | +0.2% | +1.6% | +3.6% | +0.2% | -0.2% | +10.7% | — |
| May 9, 2024 | AMC | -0.39 | -0.33 | +15.4% | 20.00 | -4.5% | -8.3% | -4.6% | -0.2% | +1.4% | +2.8% | — |
| Feb 22, 2024 | AMC | -0.44 | -0.47 | -6.8% | 17.37 | +5.8% | -0.5% | -1.4% | -1.1% | -1.2% | -1.9% | — |
| Nov 9, 2023 | AMC | -0.40 | -0.41 | -2.5% | 5.72 | -0.3% | -3.7% | +11.3% | +6.2% | +0.8% | -3.2% | — |
| Aug 10, 2023 | AMC | -0.41 | -0.34 | +17.1% | 6.74 | +0.0% | -0.4% | +0.9% | +7.8% | -1.0% | -2.1% | — |
| May 11, 2023 | AMC | -0.37 | -0.36 | +2.7% | 9.52 | -0.8% | -2.6% | -2.7% | +3.8% | -0.7% | +0.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17 | Wedbush | Maintains | Outperform → Outperform | — | $29.78 | $30.41 | +2.1% | +2.4% | -2.7% | +1.2% | -3.3% | +2.5% |
| Mar 17 | JP Morgan | Maintains | Overweight → Overweight | — | $29.78 | $30.41 | +2.1% | +2.4% | -2.7% | +1.2% | -3.3% | +2.5% |
| Feb 27 | Evercore ISI | Maintains | Outperform → Outperform | — | $29.66 | $29.55 | -0.4% | +2.6% | -2.4% | -3.0% | +0.2% | -1.7% |
| Nov 14 | JP Morgan | Maintains | Overweight → Overweight | — | $20.42 | $20.52 | +0.5% | +11.4% | -2.2% | -0.4% | +0.8% | -0.4% |
| Nov 7 | Wedbush | Maintains | Outperform → Outperform | — | $17.09 | $17.05 | -0.2% | +0.4% | +6.5% | +17.5% | -1.4% | -3.5% |
| Nov 7 | RBC Capital | Maintains | Outperform → Outperform | — | $17.09 | $17.05 | -0.2% | +0.4% | +6.5% | +17.5% | -1.4% | -3.5% |
| Aug 19 | JP Morgan | Maintains | Overweight → Overweight | — | $14.00 | $14.02 | +0.1% | -1.4% | +0.3% | +5.6% | +1.6% | -3.7% |
| Aug 8 | RBC Capital | Maintains | Outperform → Outperform | — | $12.95 | $12.99 | +0.3% | -2.1% | +2.4% | +3.1% | +2.5% | +1.5% |
| Jun 5 | RBC Capital | Maintains | Outperform → Outperform | — | $14.49 | $14.47 | -0.1% | +2.3% | +2.8% | +0.1% | +1.2% | +1.9% |
| May 16 | JP Morgan | Maintains | Overweight → Overweight | — | $14.45 | $14.48 | +0.2% | +2.3% | +0.1% | +0.5% | -1.9% | -3.9% |
| May 9 | RBC Capital | Maintains | Outperform → Outperform | — | $14.70 | $14.95 | +1.7% | -0.8% | +1.6% | +0.5% | -2.3% | -0.7% |
| Apr 21 | Wedbush | Maintains | Outperform → Outperform | — | $13.45 | $13.36 | -0.7% | -1.1% | +1.7% | +9.6% | +3.8% | -3.6% |
| Apr 3 | RBC Capital | Maintains | Outperform → Outperform | — | $15.52 | $14.90 | -4.0% | -12.5% | -15.2% | +2.8% | -2.9% | +8.8% |
| Apr 3 | Scotiabank | Downgrade | Sector Outperform → Sector Perform | — | $15.52 | $14.90 | -4.0% | -12.5% | -15.2% | +2.8% | -2.9% | +8.8% |
| Apr 2 | Piper Sandler | Maintains | Overweight → Overweight | — | $20.13 | $14.50 | -28.0% | -22.9% | -12.5% | -15.2% | +2.8% | -2.9% |
| Mar 4 | RBC Capital | Maintains | Outperform → Outperform | — | $25.53 | $25.12 | -1.6% | -4.0% | +9.0% | +5.3% | -0.4% | -1.7% |
| Dec 17 | Evercore ISI | Maintains | Outperform → Outperform | — | $32.69 | $33.37 | +2.1% | -7.7% | -0.5% | +2.6% | -0.1% | -2.6% |
| Nov 27 | Truist | Maintains | Buy → Buy | — | $32.08 | $33.16 | +3.4% | +0.4% | +2.5% | -4.4% | +1.3% | +0.3% |
| Nov 8 | Wedbush | Maintains | Outperform → Outperform | — | $35.43 | $34.96 | -1.3% | +2.7% | -2.9% | -0.4% | -5.5% | -1.2% |
| Oct 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $29.99 | $29.99 | +0.0% | +6.4% | -0.3% | +3.7% | +6.2% | +1.4% |
| Sep 20 | RBC Capital | Maintains | Outperform → Outperform | — | $29.50 | $29.94 | +1.5% | -4.1% | -6.3% | -2.2% | -0.2% | +0.5% |
| Sep 19 | Truist | Maintains | Buy → Buy | — | $19.07 | $25.75 | +35.0% | +54.7% | -4.1% | -6.3% | -2.2% | -0.2% |
| Sep 17 | RBC Capital | Maintains | Outperform → Outperform | — | $16.86 | $17.11 | +1.5% | +7.2% | +5.5% | +54.7% | -4.1% | -6.3% |
| Aug 16 | Wedbush | Maintains | Outperform → Outperform | — | $18.87 | $18.88 | +0.1% | -2.2% | +2.0% | +4.8% | +6.2% | -6.4% |
| Aug 12 | JP Morgan | Maintains | Overweight → Overweight | — | $16.45 | $16.50 | +0.3% | +3.6% | +0.2% | -0.2% | +10.7% | -2.2% |
| Jul 25 | RBC Capital | Maintains | Outperform → Outperform | — | $21.18 | $21.29 | +0.5% | -11.6% | +1.3% | -5.0% | -5.5% | -0.1% |
| Jul 10 | RBC Capital | Maintains | Outperform → Outperform | — | $22.85 | $22.92 | +0.3% | -5.8% | +3.8% | +0.4% | +2.0% | -2.9% |
| Jul 9 | JP Morgan | Maintains | Overweight → Overweight | — | $20.92 | $21.00 | +0.4% | +9.2% | -5.8% | +3.8% | +0.4% | +2.0% |
| Jul 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $18.01 | $17.99 | -0.1% | +7.6% | -5.2% | -0.5% | +6.3% | +7.7% |
| Jun 26 | Wedbush | Maintains | Outperform → Outperform | — | $17.39 | $17.77 | +2.2% | +0.5% | +0.1% | +2.9% | +7.6% | -5.2% |
| Apr 22 | RBC Capital | Maintains | Outperform → Outperform | — | $15.23 | $15.93 | +4.6% | -1.0% | +3.8% | +2.9% | -1.1% | +1.4% |
| Apr 17 | Truist | Maintains | Buy → Buy | — | $16.63 | $16.85 | +1.3% | -5.9% | -1.3% | -1.4% | -1.0% | +3.8% |
| Apr 16 | Wedbush | Maintains | Outperform → Outperform | — | $16.48 | $16.28 | -1.2% | +0.9% | -5.9% | -1.3% | -1.4% | -1.0% |
| Mar 12 | RBC Capital | Maintains | Outperform → Outperform | — | $16.75 | $16.73 | -0.1% | +5.8% | -1.7% | -2.0% | -0.9% | -8.2% |
| Nov 10 | Wedbush | Maintains | Outperform → Outperform | — | $5.72 | $5.70 | -0.3% | -3.7% | +11.3% | +6.2% | +0.8% | -3.2% |
| Aug 16 | Wedbush | Maintains | Outperform → Outperform | — | $7.30 | $7.24 | -0.8% | -1.0% | -2.1% | +1.6% | +1.1% | +0.6% |
| Aug 11 | Wedbush | Maintains | Outperform → Outperform | — | $6.74 | $6.74 | +0.0% | -0.4% | +0.9% | +7.8% | -1.0% | -2.1% |
| Jun 30 | JP Morgan | Maintains | Overweight → Overweight | — | $7.53 | $7.98 | +6.0% | +2.9% | -2.7% | +1.6% | -3.0% | -1.9% |
| Jun 28 | RBC Capital | Maintains | Outperform → Outperform | — | $7.51 | $7.95 | +5.9% | +0.7% | -0.4% | +2.9% | -2.7% | +1.6% |
| Jun 28 | Truist | Maintains | Buy → Buy | — | $7.51 | $7.95 | +5.9% | +0.7% | -0.4% | +2.9% | -2.7% | +1.6% |
| Jun 27 | Truist | Maintains | Buy → Buy | — | $6.86 | $6.88 | +0.3% | +9.5% | +0.7% | -0.4% | +2.9% | -2.7% |
| Jun 20 | JP Morgan | Maintains | Overweight → Overweight | — | $8.30 | $7.96 | -4.1% | -1.3% | -2.7% | -1.8% | -2.9% | -9.7% |
| May 16 | JP Morgan | Maintains | Overweight → Overweight | — | $9.02 | $8.86 | -1.8% | +3.8% | -0.7% | +0.2% | -1.5% | +5.7% |
| May 12 | Wedbush | Maintains | Outperform → Outperform | — | $9.52 | $9.44 | -0.8% | -2.6% | -2.7% | +3.8% | -0.7% | +0.2% |
| Feb 28 | JP Morgan | Maintains | Overweight → Overweight | — | $9.44 | $9.43 | -0.1% | +1.5% | +0.1% | -2.4% | +0.7% | -6.7% |
| Nov 4 | RBC Capital | Maintains | Outperform → Outperform | — | $10.04 | $10.27 | +2.3% | -4.7% | +0.2% | +0.1% | -2.1% | +11.6% |
| Aug 25 | Goldman Sachs | Downgrade | Neutral → Sell | — | $11.02 | $9.52 | -13.6% | -7.4% | -3.8% | +2.7% | -0.9% | +1.0% |
| May 24 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.27 | $7.13 | -1.9% | -12.7% | -10.7% | +1.6% | +5.4% | +3.0% |
| May 12 | SVB Leerink | Maintains | Outperform → Outperform | — | $7.07 | $6.94 | -1.8% | +5.7% | +4.8% | -6.9% | +1.2% | -1.6% |
| May 12 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.07 | $6.94 | -1.8% | +5.7% | +4.8% | -6.9% | +1.2% | -1.6% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | Donovan Joanne M. | CMO | Sell | 50,000 | $38.57 | $1.9M | 4,367 | -2.68% | -1.59% |
| May 4, 2026 | Donovan Joanne M. | CMO | Sell | 5,230 | $31.29 | $164K | 4,367 | -2.68% | -1.59% |
8-K
Edgewise Therapeutics, Inc. -- 8-K Filing
Jun 1
8-K · 2.02
!! High
Edgewise Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Edgewise Therapeutics (EWTX) released Q1 2026 financial results, providing investors with updates on its operational performance and financial condition for the quarter ending March 31, 2026.
May 7
8-K
Edgewise Therapeutics, Inc. -- 8-K Filing
Edgewise Therapeutics reported strong 2025 financial results and execution, positioning the company for transformative growth in the upcoming year.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Janus Henderson Group Plc | 5,915,556 | $186M | New | Mar 2026 |
| 2 | Morgan Stanley | 5,821,762 | $144M | Added | Dec 2025 |
| 3 | Braidwell Lp | 5,210,831 | $129M | — | Dec 2025 |
| 4 | Vanguard Capital Management Llc | 3,788,161 | $119M | New | Mar 2026 |
| 5 | Mpm Bioimpact Llc | 1,660,696 | $52M | — | Mar 2026 |
| 6 | Bellevue Group Ag | 1,528,518 | $48M | — | Mar 2026 |
| 7 | Soleus Capital Management, L.p. | 1,449,915 | $46M | Added | Mar 2026 |
| 8 | Bank Of America Corp /de/ | 1,327,360 | $42M | Added | Mar 2026 |
| 9 | Ubs Group Ag | 1,311,125 | $41M | Reduced | Mar 2026 |
| 10 | Fmr Llc | 1,017,052 | $32M | Added | Mar 2026 |
| 11 | Aberdeen Group Plc | 826,059 | $26M | Added | Mar 2026 |
| 12 | Qube Research & Technologies Ltd | 825,910 | $26M | Added | Mar 2026 |
| 13 | Victory Capital Management Inc | 789,043 | $25M | Added | Mar 2026 |
| 14 | Artisan Partners Limited Partnership | 659,067 | $21M | Reduced | Mar 2026 |
| 15 | Marshall Wace, Llp | 648,393 | $20M | Reduced | Mar 2026 |
| 16 | Northern Trust Corp | 576,556 | $18M | Added | Mar 2026 |
| 17 | Vanguard Portfolio Management Llc | 557,260 | $18M | New | Mar 2026 |
| 18 | Citadel Advisors Llc | 429,032 | $14M | Added | Mar 2026 |
| 19 | Healthcare Of Ontario Pension Plan Trust Fund | 404,200 | $13M | Reduced | Mar 2026 |
| 20 | Candriam S.c.a. | 501,214 | $12M | Added | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$3.96B
Enterprise Value
$3.26B
P/E (TTM)
-22.58x
Forward P/E
—
PEG Ratio
-1.23x
P/B
7.25x
P/S
—
P/FCF
-26.35x
EV/EBITDA
—
Shares Out
102.9M
Financials (TTM)
Revenue
$0
Net Income
-$167.8M
EBITDA
-$165.5M
Free Cash Flow
-$143.8M
Op Cash Flow
-$143.8M
EPS Basic
$-1.63
EPS Diluted
$-1.63
EPS Forward
$-2.09
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$552.6M
Total Liab.
$30.3M
Total Equity
$522.3M
Cash
$530.1M
LT Debt
$3.0M
Book Value/Sh
$5.07
Debt/Equity
0.01x
Current Ratio
19.85
Quick Ratio
19.85
Returns & Growth
ROE
-32.1%
ROA
-30.4%
ROIC
-36.4%
Rev Growth YoY
+0.0%
EPS Growth YoY
-12.4%
Price Returns
2W
+0.4%
1M
+10.3%
3M
+12.2%
6M
+31.2%
12M
+139.2%
Technicals
52W High
$40.77
52W Low
$12.15
50d MA
$33.80
200d MA
$25.99
RSI (14)
56.10
ATR (14)
$2.61
Beta
0.25
Avg Volume
1.6M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$38.67
High
$46.00
Low
$25.00
Median
$45.00
Data updated apr 25, 2026 8:07am
· Source: financialmodelingprep.com